Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
新闻中心
公司新闻
2026-03
2026
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China’s National Medical Products Administration (NMPA) for Chronic Weight Management
2026-03-06
2026-02
2026
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
2026-02-24
2026-01
2026
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China’s National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
2026-01-30
2026-01
2026
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
2026-01-28
2025-10
2025
Sciwind Biosciences Secures US$37 Million Series B Financing
2025-10-25
2025-10
2025
Sciwind's Investigational New Drug Approved for NASH Trial
2025-10-25
2025-10
2025
Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary
2025-10-25
2025-10
2025
Sciwind Biosciences Completes $70 Million Series C Financing and Expands Leadership Team to Advance Metabolic Disease Pipeline
2025-10-25
2025-10
2025
Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease
2025-10-25
2025-10
2025
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients
2025-10-25
<
1
2
3
4
>
